Bioventus Inc.

NASDAQ:BVS

Medical - Devices

Healthcare
$10.62 +2.11%

+$0.18 today

Market cap
$727.20M
Beta
0.67
P/E (TTM)
20.6
EPS (TTM)
$0.42
52W Low $5.81High $11.25

Volume 0.70M

Average 0.56M

BVS Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Bioventus Inc.NASDAQ: BVS

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses growth accelerates

Q1 FY2026 operating expenses of $80.77M rose 5.6% year over year, ahead of the -16.8% change in trailing-twelve-month operating expenses. Sequentially, it fell 5.8% from the prior quarter. Over 3 fiscal years it compounded at -13.4% a year.

Context

  • Operating expenses amounted to 57.0% of revenue in FY2025, down 12.8 pp from a year earlier.
  • Operating expenses increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +5.6% holds above the trailing-twelve-month pace of -16.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$80.77M-5.8% QoQ
Last fiscal yearDec 2025
$323.88M-19.1% YoY
LTMMar 2026
$329.3M-16.8% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.6%——
1 year-19.1%——
3-year CAGR-13.4%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
323.88M USD
Year-over-year change
-19.1%
4-year CAGR
+2.7%

Operating Expenses vs competitors

How BVS compares with its peers on the latest reported figures

  • BVS's LTM Mar 2026 operating expenses of $329.3M is the 5th highest of the 9 companies compared; the peer median is $313.24M.
  • Its year-over-year change of -16.8% is the lowest of 9, against a peer median of -2.2%.
  • Operating expenses amounts to 57.1% of revenue for BVS, versus a peer median of 68.7%.
BVS Competitors Peer median
Operating Expenses for BVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNNSmith & Nephew plcFY2025$3.41B -0.3%+1.6%55.4%
IARTIntegra LifeSciences Holdings CorporationLTM Mar 2026$751.14M -12.7%+2.0%45.7%
OFIXOrthofix Medical Inc.LTM Mar 2026$602.92M -6.4%+21.0%73.0%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$350.61M -4.1%+4.5%68.3%
BVSBioventus Inc.LTM Mar 2026$329.3M -16.8%-13.4%57.1%
MDXGMiMedx Group, Inc.LTM Mar 2026$275.88M +17.5%+6.3%70.8%
TELATELA Bio, Inc.LTM Jun 2026$88.2M +0.3%+10.1%110.4%
ANIKAnika Therapeutics, Inc.LTM Mar 2026$80.38M +22.8%+2.5%69.1%
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$72.7M -7.6%+25.6%59.6%
Peer median (excluding BVS) $313.24M-2.2%+5.4%68.7%

Competitors are the stored peer set for BVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue430.9M512.12M512.35M573.28M568.09M
Cost of Revenue128.19M181.04M184.15M185.05M185.66M
Gross Profit302.71M331.08M328.19M388.23M382.43M
Gross Margin70.3%64.6%64.1%67.7%67.3%
Research & Development19.04M23.85M13.45M13.64M12.11M
Selling, General & Admin254.25M332.13M303.88M327.09M311.77M
Operating Expenses290.65M498.31M409.92M400.21M323.88M
Depreciation & Amortization34.88M55.4M57.37M49.56M47.01M
EBITDA45.48M(121.61M)(23.07M)39.22M99.21M
EBITDA Margin10.6%-23.7%-4.5%6.8%17.5%
Operating Income12.06M(167.23M)(81.73M)(11.98M)58.55M
Operating Margin2.8%-32.7%-16.0%-2.1%10.3%
Interest Income00000
Interest Expense1.11M12.02M40.68M38.79M26.49M
Other Income / Expenses(2.57M)(21.79M)(39.39M)(37.15M)(32.84M)
Income Before Tax9.49M(189.03M)(121.11M)(49.13M)25.71M
Pre-Tax Margin2.2%-36.9%-23.6%-8.6%4.5%
Income Tax Expense(1.97M)(44.37M)85K(5.29M)(1.57M)
Net Income19.38M(158.7M)(156.23M)(33.54M)22.73M
Net Margin4.5%-31.0%-30.5%-5.9%4.0%
EPS (Basic)(0.15)(2.59)(2.49)(0.52)0.34
EPS (Diluted)(0.15)(2.59)(2.49)(0.52)0.33
Weighted Avg Shares45.47M61.39M62.65M65.36M66.62M
Weighted Avg Shares (Diluted)45.47M61.39M62.65M65.36M68.91M

Bioventus Inc.

NASDAQ:BVS

Intrinsic Alpha fair value

Locked

Current Price

$10.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.